Liver Diseases  >>  MK-3281  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-3281 / Merck (MSD)
NCT00635804: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Completed
1
60
NA
MK-3281, Placebo to MK-3281
Merck Sharp & Dohme LLC
Hepatitis C
12/09
12/09

Download Options